Department of Cell and Molecular Pharmacology
& Experimental Therapeutics
Hollings Cancer Center
Seeking highly motivated individuals to work in the area of cellular signaling related to cancer development and progression. Candidates must have experience in molecular biology, biochemistry, and cell biology. Research in the laboratory is focused on two major areas: 1. RAS GTPase signaling and transformation; and 2. Compartmentalized signaling by the intersectin (ITSN) scaffold protein. We have identified a novel allosteric regulatory site in RAS that is involved in the dimerization and nanoclustering of RAS at the plasma membrane (Spencer-Smith et. al. Nat. Chem. Biol, 2016 doi: 10.1038/nchembio.2231). Targeting this site blocks oncogenic RAS-mediated signaling and transformation by inhibiting RAS-induced dimerization and activation of the RAF kinase. Current studies are examining the role of RAS dimerization/nanoclustering in additional RAS effector pathways as well as using novel affinity reagents to probe isoform-specific differences in RAS signaling. In addition, we are studying the role of the ITSN scaffold protein in regulating endocytosis and cellular signaling and its involvement in human cancers, in particular, neuroblastoma (Herrero-Garcia, E. and O’Bryan,J.P., BBA-MRC, doi: 10.1016/j.bbamcr.2016.10.005; Russo, A. and O’Bryan, J.P., Oncogene, doi: 10.1038/onc.2011.643; Harris, J., et. al. J. Pediatr. Hematol. Oncol. doi: 10.1097/MPH.0000000000000931). Current projects center on ITSN’s role in regulating RAS family GTPases, lipid kinases, ubiquitin ligases, protein trafficking pathways, and the importance of these ITSN-regulated pathways in human disease, particularly cancer.
Applicants must have a Ph.D. or M.D. degree, and be eligible for employment in the U.S. These are non tenure-track positions, with renewal dependent on continued funding. Start date is negotiable although preference will be given to candidates that can begin immediately. Salary range is commensurate with experience according to NIH scale for postdocs. The position is a benefit eligible position. For fullest consideration send electronic file containing statement of research interest and experience, curriculum vitae, and names of three references to: Dr. John P. O’Bryan, email: firstname.lastname@example.org. Applicants should also apply online at: http://careers.pageuppeople.com/756/cw/en-us/job/510339/univ-postdoctoral-scholar-pharmacology
Founded in 1824, The Medical University of South Carolina (MUSC) is now the core of the state’s largest medical complex and one of its largest employers with over 11,000 employees. Our research laboratory space exceeds 1 Million square feet. Extramural research funding awards to MUSC in 2017 exceeded $250 million. In addition, MUSC was named on Forbes first-ever list of America’s Best Employers for Diversity.
The Hollings Cancer Center (HCC) is the only NCI-Designated Cancer Center in South Carolina. Currently, HCC researchers hold approximately $45 Million in annual extramural cancer research funding with $23 Million originating from the NCI.
MUSC is located in historic Charleston, South Carolina. The weather is beautiful year-round, with temperatures rarely dropping below freezing during winter. There are several beaches within minutes of the city and the mountains are only three hours away. In addition to these amenities, the art, history, food, and festivals make Charleston an outstanding place to live.